This case note analyses the General Court’s judgment in Arysta Lifescience v EFSA (Case T-222/23), which addresses the tensions arising from the disclosure of the lists of co-formulant in the context of the EU risk assessment of pesticides. The decision consolidates the General Court’s interpretation of “information relating to emissions into the environment” under Article 6(1) of Aarhus Regulation, confirming its applicability to the list of co-formulants contained in representative products.

This article analyses the recent reform to the EU’s genetically modified organisms (GMO) regime which allows Member States to restrict the cultivation of GMO on their territory for reasons that do not relate to issues of health and safety or the environment. By allowing for national differentiation – although on legally questionable grounds – new Article 26b of Directive 2001/18/EC has been presented as a solution to overcome the impasse in GMO decision-making. However, this article finds that the reform fails to provide a solution for the EU regime’s most pressing problem, namely its disregard for scientific uncertainty and disagreement.